Article By:
Benzinga
Thursday, July 29, 2021 10:49 AM EDT
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues, partially offset by lower Kuvan product revenues.
In this article: BMRN